How Ph.D. was paid
$1.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Other | Total |
|---|---|---|---|---|---|
| Nicholas A. Saccomano, Ph.D.President and Chief Executive Officer | $600,000 | $609,934 | $247,500 | $10,500 | $1,467,934 |
| Samuel Agresta, M.D.Chief Medical Officer | $482,000 | $211,131 | $144,600 | $14,000 | $851,731 |
| Jason Leverone, C.P.A.Chief Financial Officer | $444,000 | $304,967 | $133,200 | $14,000 | $896,167 |
What changed and why
- $1.5MNicholas A. Saccomano received total compensation of $1,467,934 in 2025, down significantly from $9,515,165 in 2024.
- $610KOption awards for the CEO dropped to $609,934 in 2025 compared to $8,773,422 in the prior year.
- $600KNamed Executive Officers received base salaries of $600,000 for the CEO, $482,000 for the CMO, and $444,000 for the CFO.
- None of the Named Executive Officers received an increase to their annual base salary for the year 2025.
- $248KNon-equity incentive plan compensation of $247,500 was earned by the CEO based on 2025 company goal achievements.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.